

Program Agenda

Developing Countries Vaccine Manuracturers Network 18th Annual General Meeting 25th-28th September 2017 Seoul, The Repulbic of Korea

08:30 – 09:00	Registrations				
09:00 – 12:30	PATH /UNICEF/WHO workshop on Innovative Solutions for Vaccine Supply and Distribution / Grand Ballroom A • Chair: D. Kristensen (Director, PATH) • Co-chair: H. Kim (Specialist, LG Chem)		DCVMN Executive Committee Meeting / Room #1		
09:00 - 09:05	Introduction		Private meeting for		
09:05 – 09:20	Novel primary containers	Overview and status of novel primary containers. D. Zehrung (Portfolio Leader, PATH)	Executive Committee members: by Invitation Only		
09:20 – 09:30	-	Q&A			
09:30 – 10:20	Bar codes and serial numbers	Training session on bar codes and serial numbers. <i>U. Kreysa (Vice President, GS1)</i>			
10:20 – 10:30	-	Q&A	-		
10:30 - 11:00	Coffee Break / Ha				
11:00 – 11:30	Controlled temperature chain use of vaccines	Status of CTC qualified vaccines and priority vaccines for future CTC use and ongoing work to introduce CTC in countries and understand demand for CTC vaccines. <i>AL. Kahn (Technical Officer, WHO)</i>	Private meeting for Executive Committee members: by Invitation Only		
11:30 – 11:40		Q&A			
11:40 – 11:55		Resources/guidance available from WHO on CTC and barcoding/serial numbers. <i>A. Meek (Scientist, WHO)</i>			
11:55 – 12:10		WHO & UNICEF's positions on bar coding, total system effectiveness, CTC, environmental management, sustainable procurement, Vaccine Arrival Reports. <i>I. Lewis (Contracts Specialist, UNICEF SD)</i>			
12:10 – 12:30	-	Q&A	1		
12:30 – 14:00	Lunch / Grand Ballroom B				
14:00 - 17:00	DCVMN General Assembly / Grand Ballroom A*				
14:00 – 15:30	DCVMN General Assembly: for DCVMN members only				
15:30 – 16:00	Coffee Break / Hall #1&2				
16:00 – 17:00	DCVMN General Assembly: for DCVMN members only				
17:00 – 17:30	Free Time for Networking / Hall #1&2				
17:30 – 18:30	 Welcome Satellite Symposium on Innovative Technologies / Grand Ballroom A Chair: M. Payne (Principal Technical Consultant, Merck Millipore) Co-chair: G. Jagschies (Senior Director, GE Healthcare) 				
17:30 – 17:45	Development of a cost effective purification process for Vi polysaccharide S. Kothari (Former IVI Senior Research Scientist)				
17:45 – 18:00	Innovations on thermostability monitoring: VVM+ and VVM200 M. Rush (Executive Director, Temptime Corporation)				
18:00 – 18:15	EV71 inactivated vaccine (human diploid cell) development, purification and evaluation. L. Liu (Scientist, IMBCAMS) & M. Lundgren (Customer Applications Director, GE Healthcare)				
18:15 – 18:30	Q&A				
18:30 – 19:00	Free Time for Networking / Hall #1&2				

* Free time for Networking / Hall #1&2 for other delegates.

00.00	Desistrations				
08:30 - 09:00	Registrations				
09:00 - 10:15	Plenary Opening Session / Grand Ballroom				
09:00 – 10:15	Chair: M. Datla (Brogident, DC)(MN)	Opening Address <i>M. Datla (President, DCVMN)</i>			
	(President, DCVMN) Co-chair: 	Welcome Speech by Host J. Ahn (Executive Vice President, SK Chemicals)			
	M. Park (CEO, SK Chemicals)	Inaugural Address Korean Ministry of Health and Welfare			
		Inaugural Keynote Lecture S. Berkley (CEO, GAVI)			
10:15 – 10:45	Coffee Break / Hall #1&2				
10:45 – 12:30	Epidemic/Pandemic Forun	n / Grand Ballroom			
10:45 – 11:45	Chair: A. Precioso (Clinical Director, Instituto Butantan)	Accelerating vaccine development for epidemic preparedness Stop future epidemics <i>R. Hatchett (CEO, CEPI)</i>			
	Co-chair:	Eliminate Yellow Fever Epidemics (EYE) Initiative S. Briand (Director, WHO Health Emergencies Programme)			
	M. Suhardono (Marketing Director, BioFarma)	The MERS Vaccine Initiative (candidates) J. Kim (Director General, IVI)			
11:45 – 12:30	Panel discussion Moderator: 	New potential epidemic/pandemic vaccines Panellists:			
	M. Friede (Coordinator IVR, WHO)	O. Leroy (Executive Director, EVI), A. Precioso (Clinical Director, Instituto Butantan), M. Zuma (General Director, Bio-Manguinhos), S. Desai (Senior Vice President, Zydus Cadila), R. Hatchett (CEO, CEPI)			
12:30 - 14:00	Lunch / Maple Hall, Oak Room and Orchid Hall (4th Floor)				
14:00 - 17:00	Innovative Partnerships Fo	orum / Grand Ballroom			
14:00 – 15:30	• Chair: K. Ella	Public-private partnerships to eliminate neglected tropical diseases <i>B. Abela-Ridder (Team Leader, WHO)</i>			
	(Chairman &Managing Director, Bharat Biotech)	The ZIKAVAX partnership O. Leroy (Executive Director, EVI)			
	• Co-chair:	African Vaccine Manufacturers Initiative (AVMI) W. Ampofo (Chairperson, AVMI)			
	M. Friede (Coordinator IVR, WHO)	The vision of partnerships for developing countries vaccine industry <i>A. Oswald (Director, BMGF)</i>			
15:30 – 16:00	Coffee Break / Hall #1&2				
16:00 – 17:00	Panel discussion • Moderator: G. Rockman	Challenges and benefits of bringing industry together Panellists: K. Ella (Chairman & Managing Director, Bharat Biotech),			
	(Partner, GHIF)	B. Abela-Ridder (Team leader, WHO), P. Khoury (CEO,Nanotherapeutics), A. Gil (President, Sinergium Biotech), M. Makhoana (CEO, Biovac)			
17:00 – 19:00	Free Time for Networking	/ Hall #1&2			
19:00 – 21:00	Cultural Dinner / Grand Ballroom	Introductory speech by host J. Ahn (Executive Vice President, SK Chemicals)			
		Cultural Dinner sponsored by SK Chemicals for all delegates			

DAY 3 - Sep	otember 27th \	Vednesday			
09:00 – 10 :40	Regulatory Forum convergence / Gra	: Tools to increase regulatory and Ballroom A	Procurement & Financing Forum / Grand Ballroom B		
09:00 – 10:40	 Chair: Y. Sohn (Former Director General, NIFDS, MFDS Korea) Co-chair: N. Dellepiane 	Tools to accelerate vaccines' registration in developing countries <i>E. Cooke</i> <i>(Head of Regulation, WHO)</i>	 Chair: R. Jain (Joint Managing Director, Panacea Biotech) Co-chair: M. Makohana (CEO, Biovac) 	WHO V3P goals T. Cernuschi (Team Leader, Vaccine Supply, Technologies & Financing, WHO)	
		Speeding vaccines registration in developing countries S. Bhaskaran (Program Officer, BMGF)		UNICEF stockpiling strategies and priorities S. Rautio (Deputy Director, UNICEF)	
		Vaccine Registration requirements and options for alignment <i>N. Dellepiane (Consultant)</i>		Gavi – current initiatives, <i>M. Malhame</i> (Head of Market Shaping, Gavi)	
		AVAREF's experience with joint reviews to improve regulatory capacity. <i>B. Akanmori</i> (<i>Regional Advisor, AVAREF</i>)		Unlocking access to new vaccines <i>E. Torreele</i> (<i>Executive Director, MSF</i>)	
		Q&A		Q&A	
10:40 – 11:00	Coffee Break / Hall #1&2				
11:00 – 12:30	Regulatory Convergence Panel Discussion / Grand Ballroom A		Innovative Procurement & Financing Panel Discussion / Grand Ballroom B		
11:00 – 12:30	• Moderator: N. Dellepiane	Panel A) Options to improve regulatory alignment: Y. Sohn (Former Director General, NIFDS, MFDS Korea), B. Akanmori (Regional Advisor, AVAREF), H. Iyer (Senior Advisor, BMGF) Panel B) Mechanisms to accelerate emergency use of vaccines: E. Cooke (Head of Regulation, WHO), S. Bhaskaran (Program Officer, BMGF), R. Hatchett (CEO, CEPI), D. Do (General Director, Vabiotech)	• Moderator: S. Sobti (Senior Manager, CHAI)	Panel A) Pool procurement of vaccines: S. Rautio (Deputy Director, UNICEF), L. Meng (Deputy Director, CNBG), O. Vargas (Procurement Specialist, PAHO) Panel B) Financing: S. Briand (Director, WHO), A. Oswald (Director, BMGF), M. Malhame (Market Shaping Head, Gavi)	
12:30 – 14:00	Lunch / Maple Hall, Oak room (4th Floor)				
14:00 - 15:00	Tech Transfer Forum: Tech transfer to DCVMNs / WHO PQ / Grand Ballroom B Grand Ballroom A				
14:00 – 15:00	• Chair: V. Pavliak (Head of Vaccine Development, IVI)	Analytical technology transfer to DCVMN countries <i>MH. Nahm (Professor, Univ.</i> of Alabama at Birmingham)	• Chair: E. Cooke (Head of Regulation, WHO)	Overview of WHO PQ processes C. Rodriguez (Group Lead, Vaccines PQ, WHO)	

	• Co-chair: S. Desai (Senior Vice President, Zydus Cadila)	Novel recombinant technology platform <i>A. Tomar (CEO, CPL)</i> Technology transfer partnerships to improve vaccine supply in Bangladesh <i>A. Muktadir (Chairman & Managing Director, Incepta)</i>	• Co-chair: N. Dellepiane	Vaccines PQ updates: CTD format <i>A. Meek (Scientist, WHO)</i> Facilitating access of products under emergency situation: EUAL process <i>C. Rodriguez</i> (Group Lead, Vaccines PQ, WHO)
15:00 - 16:00	Innovative Vaccines Session / Grand Ballroom A		Polio Vaccines / Grand Ballroom B	
15:00 - 16:00	 Chair: H. Kim (Vice President, Head of R&BD, SK Chemicals) Co-chair : S. Prasad (President, Bharat Biotech) 	Developing the first GBS vaccine <i>P. Tippoo</i> (<i>Head of Science & Innovation, Biovac</i>) New Rotavirus vaccines <i>S. Jadhav</i> (<i>Executive Director,</i> <i>Serum Institute of India</i>) Introducing new Fill-seal technology <i>Y. Baek (CEO, EuBiologics</i>) Evaluation of MDCK cell- derived Influenza H7N9 vaccine candidate	 Chair: A. Homma (Senior Scientific Advisor, Bio-Manguinhos /Fiocruz) Co-chair: AL. Kahn (Technical Officer, WHO) 	Global update on polio eradication & containment <i>S. Zipursky (Advisor, WHO)</i> Update on polio vaccines supply and forecasts <i>I. Lewis</i> (<i>Contracts Specialist, UNICEF</i> <i>SD</i>) Manufacturers' perspectives: New sabin IPV Y. Zhang (Associate President, Tiantan Bio) & <i>L. Meng (Director, CNBG)</i> OPV <i>MR. Roestan</i> (<i>Marketing Director, BioFarma</i>) Discussion
16:00 - 16:30	Coffee Break / Ha	<i>M. Lee (Investigator, NIIDV)</i>		
16:30 - 17:30	Plenary Closing Session / Grand Ballroom			
16:30 - 17:30	 Chair: M. Datla (President, DCVMN) Co-chair: V. Bencomo (General Director, Finlay Vaccine Institute) 	Closing Keynote Lecture Vaccines innovation across the life cycle <i>M. Friede (Coordinator IVR, WHO)</i> Closing Remarks <i>Host of AGM 2018</i>		

Thursday 28th: optional site visit to GE-Healthcare Training laboratories in the morning and afternoon visit to IVI R&D laboratories, in Seoul.

